The largest review of menopause and muscle measured what hormone therapy actually preserves. The answer fits in the palm of your hand.
The entire theory that estrogen decline destroys muscle is built on measuring only half the equation. Nobody has ever measured muscle protein breakdown in menopausal women. Zero studies.
Across twelve trials and 4,474 women, the largest meta-analysis of hormone therapy and muscle measured how much lean mass HRT actually preserves. [1]
The answer was 0.06 kilograms.
That is the weight of a single egg.
One egg — not per person, across the entire pooled analysis. The result did not reach statistical significance. The confidence range dipped below zero, meaning hormone therapy might have preserved nothing at all.
Menzies and colleagues at the University of Nottingham reviewed what science knows about menopause, sex hormones, and what happens to muscle.
Their 2026 review in the Journal of Cachexia, Sarcopenia and Muscle covered every type of evidence available. That included studies tracking women through the transition, snapshots comparing menopausal groups, lab work measuring how fast muscle rebuilds, and trials testing what hormones actually do to muscle tissue.
The women studied ranged from their late teens to their early seventies, spanning every menopausal stage. Most were healthy and not using hormones. Nearly all were assessed using dual-energy X-ray absorptiometry — the standard body-composition scanning tool.
What they found does not match the story millions of women have been absorbing. The decline is real. The blame may not be.
The decline is real. The hormonal explanation is not proven — and the muscle-building machinery she was told was shutting down is running faster than at 30.
- Women lose roughly 5.7 percent of lean mass after menopause — but normal aging accounts for at least four percentage points of that number.
- Postmenopausal women showed 20 to 40 percent higher muscle-building activity at the cellular level than younger women or age-matched men — the opposite of what most people expect.
- The intervention that produced the most muscle required no prescription — body weight exercises and resistance bands over twelve weeks.
- The review's own authors describe the evidence linking menopause, hormones, and muscle loss as 'limited and insufficient' for robust conclusions.
Where the 5.7 Percent Actually Comes From
Women do lose lean mass during menopause. Seven of eleven cross-sectional studies confirmed it, and four of five long-term tracking studies agreed. Postmenopausal women had roughly 5.7 percent less lean mass than premenopausal women. Perimenopausal women sat in between, at 2.5 percent less.
If you have noticed your arms losing definition at 50 despite consistent training, those numbers land. The data says you are not imagining it.
But the review found something that most coverage of menopause and muscle leaves out.
The average age gap between the premenopausal and postmenopausal groups in these studies was ten years. Normal aging — independent of any hormone — causes roughly 0.4 percent muscle loss per year. Over a decade, that accounts for four percentage points of the observed 5.7.
Four out of 5.7 is not a footnote. It is most of the number.
The review does not hedge: these data "do not suggest a causal link" between the hormonal decline during menopause and muscle loss. Less physical activity, more sitting, and shifts in body fat all track with the transition. None of them require a hormonal explanation.
The muscle loss is real. The assumption that hormones caused it is unproven. What the review describes is a misattribution problem: the timing coincides with menopause, but the evidence points at least as strongly toward aging and behavior.
The Factory That Will Not Shut Down
If estrogen decline were destroying muscle from the inside, the first place it should show up is at the cellular level — in the rate at which muscle tissue builds new protein.
It does show up. But in the opposite direction.
Three of seven studies found that postmenopausal women had higher fasted muscle protein synthesis — the rate at which their bodies build new muscle tissue at rest. The increase ranged from 20 to 40 percent compared to younger women or men their own age. Four of five studies found that older women also synthesized muscle protein faster than men their own age.
The muscle-building factory is not shutting down. It is running faster than at 30.
This is the paradox the review lays bare: the machinery that builds muscle is more active after menopause, yet lean mass is declining. If the factory is overproducing, something else must be tearing down what it builds.
That something else is muscle protein breakdown — the demolition side of the equation. And here is where the review delivers its most consequential finding: no study has ever measured muscle protein breakdown across the menopausal transition in humans.
Not one. The entire theory that estrogen protects muscle is built on measuring half the equation. Nobody has measured the other half.
The factory is running. Nobody checked the wrecking crew.
Resistance bands and body weight exercises produced thirteen times more muscle than hormone therapy across thousands of women — and postmenopausal women responded exactly as well as premenopausal women.
Thirteen Times More From a Resistance Band
The hormonal route offered one egg across thousands of women. A 2025 trial at the University of Exeter tested what works without a prescription. [2]
Seventy women — pre-, peri-, and postmenopausal — completed twelve weeks of resistance training using body weight exercises and resistance bands. No gym membership required. No hormones administered.
The result: 0.79 kilograms of lean mass gained. Hip strength increased by 19 to 20 percent. Balance improved by 12 to 13 percent. Some gains appeared in as little as four weeks.
That is thirteen times more muscle than the entire meta-analysis attributed to hormone therapy.
The part the researchers themselves did not expect: there was no difference between menopausal groups. Premenopausal, perimenopausal, and postmenopausal women all responded the same way to the same program. The team had hypothesized that postmenopausal women would gain less. They were wrong.
Body weight exercises and resistance bands. Twelve weeks. Ninety-eight percent attendance. The intervention that actually moved the needle did not require a prescription.
How Muscle Got Lumped In
The menopause conversation has changed. Advocates have pushed for better research, better symptom care, and better attention to a transition that medicine long dismissed. That movement is overdue and legitimate.
Within that movement, muscle has been listed alongside bone, brain, and metabolism as tissue damaged by estrogen deficiency. The framing treats all four equally — as though the evidence for each is equally strong.
For bone, it is. Postmenopausal women can lose up to 20 percent of bone density in the years following menopause. For vasomotor symptoms — hot flashes and night sweats — roughly 80 percent of women experience relief with hormonal treatment.
For muscle, the largest pooled analysis produced one egg. [1] The meta-analysis itself concluded that "interventions other than hormone therapy should be explored." Combining resistance training with hormone therapy offered no additional muscle benefit over training alone.
The global menopause market reached 17.8 billion dollars in 2024. [3] Dietary supplements accounted for 94 percent of that revenue.
Listing muscle alongside bone conflates strong evidence with weak evidence. The advocacy is right about bone and brain. For muscle, the data points somewhere else entirely.
Postmenopausal women showed 20 to 40 percent higher muscle protein synthesis than younger women or age-matched men. The factory that was supposed to be shutting down is running faster than it was at 30.
What the Gaps Honestly Look Like
A finding this consequential earns every caveat.
The Menzies review is a narrative review, not a systematic review. It did not follow the formal search protocols or quality grading that a systematic review requires. The conclusions represent expert synthesis, not pooled statistical analysis.
The Exeter trial — the resistance band study that produced the 0.79-kilogram result — enrolled 70 women, a small sample by clinical standards. [2] The trial was partly funded by Pvolve, a fitness equipment company, and used low-impact resistance only. Heavier training might produce different results.
The muscle protein synthesis data showing 20 to 40 percent higher rates in postmenopausal women comes from short laboratory measurements lasting hours, not long-term tracking. Those acute snapshots may not capture what happens over months of daily living.
And the demolition side — muscle protein breakdown — remains completely unmeasured. Nobody can say whether estrogen protects muscle by slowing breakdown because nobody has run that study in humans.
None of these gaps change the central finding. They sharpen it. The review's own authors write that the evidence linking menopause, hormone changes, and muscle loss is "limited and insufficient to make any robust conclusions." That sentence does not weaken their review. It is the review's most trustworthy line — an honest accounting of where science stands and where the holes remain.
The direction is consistent across independent teams. A meta-analysis of 27 randomized trials found that resistance training — particularly three sessions per week — produced the clearest evidence for improving lean mass in menopausal women. [4]
A separate review of 32 studies concluded that estrogen levels after menopause are not directly associated with muscle mass or function. The mechanisms of estrogen signaling in aging muscle remain poorly understood. [5]
Different teams. Different methods. The same direction: training stimulus, not hormonal supplementation, is the variable that moves the needle.
The muscle-building factory is running. Resistance training works regardless of menopausal stage. The hormonal solution that millions of women consider for muscle specifically adds the weight of one egg across the largest analysis ever conducted.
Your body is not broken. Your training was always the answer.
But there is a question the review does not answer. If the body composition shift during menopause is not mainly about estrogen eating muscle, what is actually happening to your body — and when?
That timeline is the subject of one of the longest-running studies of its kind — 17 years tracking 1,246 women through every stage of the transition.
The most effective muscle intervention in this research required no medical consultation and no monthly subscription. The trial that produced the largest measurable gains used body weight exercises and resistance bands, completed three times per week, with some improvements appearing in as little as four weeks.
A separate meta-analysis of 27 trials identified the same pattern — resistance training three times per week, for 20 to 45 minutes per session, produced the strongest lean mass improvements in menopausal women. Sessions longer than 45 minutes showed smaller effects, suggesting intensity and consistency matter more than time spent.
The evidence does not say hormone therapy is worthless — it remains well-supported for bone density, hot flashes and night sweats, and cardiovascular health. For muscle specifically, the research points to a different tool entirely.
What other research found
What this means for you
The protein synthesis data is specific to your stage. Three studies found that postmenopausal women had higher fasted muscle-building activity at the cellular level than younger women or men their own age — running 20 to 40 percent faster, not slower.
The muscle-building pathway that was supposed to be failing is the one that works the most. And resistance training activates it at every stage of the transition.
The machinery is running. The bottleneck is not your biology — it is your stimulus.
The hormone most associated with menopause treatment — estradiol — did not stimulate muscle protein synthesis in the one study that tested it directly. Testosterone and progesterone did, producing roughly 50 percent increases. The hormone that defines most prescriptions is not the one that activates the muscle-building pathway.
The largest pooled analysis of hormone therapy and lean mass found a nonsignificant result across twelve trials and more than four thousand women.
Hormone therapy remains well-supported for other symptoms. For muscle, the evidence points to a different intervention.
The fastest rate of lean mass change happens during perimenopause — not after. Two long-term tracking studies that separated the transition into stages both found the decline accelerated during the perimenopausal years, then stabilized after menopause.
The review found that behavior changes — reduced physical activity, increased sitting, shifts in body composition — track closely with the transition and may explain more of the observed decline than hormonal shifts alone.
The perimenopausal window appears to be where the trajectory bends. The research suggests that what happens during those years shapes what the body looks like after.
Before you change anything
Healthy, non-hormone-using women make up the vast majority of the populations studied in this review. Most participants were from Western countries, recruited through clinical or university settings.
The review notes that animal models of menopause — where ovaries are surgically removed — produce more extreme estrogen deficiency than natural human menopause. Findings from those animal studies may not translate directly to what happens in women going through the natural transition.
Racial and ethnic diversity is largely absent from this evidence base. A separate systematic review found that 24 of 32 studies did not report participant race or ethnicity at all.
This is a narrative review, not a systematic review. It did not follow formal search protocols or use standardized quality grading. The conclusions represent expert synthesis — the authors read and interpreted the evidence, rather than pooling it statistically.
Ten of eleven cross-sectional studies used a scanning tool that overestimates muscle mass. The body-composition method used in nearly all this research cannot distinguish muscle from water, organ tissue, and connective tissue. The actual muscle loss may be larger — or smaller — than the numbers suggest.
The muscle protein synthesis data comes from short laboratory measurements lasting hours, not long-term tracking. Those snapshots may not capture what happens over months of daily living.
The direction of evidence is consistent across independent teams. Multiple research groups using different methods all point the same way: training stimulus, not hormonal supplementation, is the variable that moves the needle for muscle.
The individual studies, however, are not definitive. The review itself is a narrative synthesis, not a meta-analysis. The largest interventional trial enrolled 70 women — meaningful, but not large by clinical standards. The meta-analysis that produced the 0.06-kilogram finding was rated low quality by its own grading system.
Strong enough to shift a decision about supplements. Honest enough to say the mechanism question — how estrogen affects muscle protein breakdown — remains completely unanswered.
The review explains what estrogen does not do for muscle. It does not explain what is happening to the rest of her body during the transition — why fat redistributes, when lean mass stabilizes, and why the scale barely moves while everything underneath shifts.
A seventeen-year study tracked 1,246 women through every stage of menopause, measuring body composition changes year by year. The timeline it reveals is the natural next question after discovering that hormones are not the primary driver of the muscle change.
What This Study Found
All findings from this paper, in plain language.
- Women lost roughly two to six percent of their lean mass across the menopausal transition, with the largest differences appearing in postmenopausal women.
- The fastest rate of lean mass loss happened during perimenopause — not before or after — in the studies that separated the transition into stages.
- Nearly every study used a scanning tool that overestimates muscle mass, which means the real changes could be larger than the numbers suggest.
- Postmenopausal women showed higher muscle-building activity at the cellular level than younger women in three of seven studies — the opposite of what most people expect.
- No study has ever measured muscle protein breakdown across the menopausal transition — leaving half of the muscle-balance equation completely unknown.
- Older women's muscle-building response to exercise and protein may be slower to activate than younger women's, though the evidence is mixed.
- Menstrual cycle phase does not change how fast muscle builds or breaks down at rest or after exercise in premenopausal women.
- Taking birth control pills does not affect muscle gains from resistance training, though pill users may have slightly lower resting muscle-building rates.
- Testosterone and progesterone stimulated muscle building in postmenopausal women, but estradiol — the hormone most associated with menopause treatment — did not.
- Across twelve trials and more than four thousand women, hormone therapy preserved the weight of a single egg in lean mass — a result that did not reach significance.
- Animal and cell studies suggest estrogen may slow muscle breakdown, but human evidence for this mechanism remains speculative and unsupported.
- Postmenopausal women still gain muscle from resistance training, though some evidence suggests the gains may be smaller than in younger women or men.
- The decline in lean mass during menopause cannot be separated from normal aging — moving less, sitting more, and gaining fat all contribute independently of hormones.
The mechanistic case for estrogen protecting muscle is not imaginary. In laboratory settings, estradiol promotes satellite cell proliferation — the repair cells that help rebuild muscle after damage. Animal studies show that removing estrogen increases the expression of genes linked to muscle breakdown, and replacing it reverses those changes.
In postmenopausal women, one study found that estradiol supplementation reduced the activity of breakdown-related genes in women who were recently postmenopausal — but the same treatment increased their activity in women who had been postmenopausal for longer. Timing may matter more than anyone anticipated.
The International Menopause Society reviewed the clinical trial evidence and reached the same conclusion as the Menzies review: hormone therapy has not shown meaningful muscle benefits in human trials. Recent systematic reviews have confirmed the pattern — showing limited evidence for grip strength benefit and minimal physical performance improvements from hormone therapy.
Both sides of the debate agree on the same uncomfortable sentence: the evidence is insufficient. The cellular data says estrogen should help. The clinical data says it has not — at least not at the doses, durations, and populations tested so far. Whether that changes with better study design is an open question the current evidence cannot answer.